Vatiquinone Recieves CRL, RAINBOWFISH Study Published in NEJM, Hearing Aids Show Protective Effects Against Dementia
Published: | Updated:
Neurology News Network. for the week ending August 23, 2025. [WATCH TIME: 4 minutes]
NeurologyLive® Staff
Advertisement
Articles by NeurologyLive® Staff
Vormatrigine Reduces Seizures in Phase 2 RADIANT Study, Postpartum Depression in MS Women, Ianalumab Produces Significant Phase 3 Data in Sjögren’s disease
Published: | Updated:
Neurology News Network. for the week ending August 16, 2025. [WATCH TIME: 4 minutes]
Elecsys Blood Test Gains EU Approval, FDA Expands Fremanezumab Indication Into Pediatrics, VX-993 Fails Phase 2 Pain Trial
Published: | Updated:
Neurology News Network. for the week ending August 9, 2025. [WATCH TIME: 4 minutes]
IHL-42X Performs in Phase 2 RePOSA Study, ATH434 Eyes Phase 3 Multiple System Atrophy Trial, 4-Year Data on Lecanemab Unveiled
Published: | Updated:
Neurology News Network. for the week ending August 2, 2025. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Gefurulimab Positive Phase 3 Data Released, PoNS Device Eyes Stroke Indication, AD109 Performs in Phase 3 LunAIRo Trial
Published: | Updated:
Neurology News Network. for the week ending July 26, 2025. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Sleep Agent Oveporexton Meets End Points in Phase 3 Studies, XPro Shows Mixed Phase 2 Data, Ultraprocessed Food Consumption Linked to Parkinson's Features
Published: | Updated:
Neurology News Network. for the week ending July 19, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 18, 2025.
Here's some of what is coming soon to NeurologyLive® this week.
FDA Approves Updated Donanemab Labeling, BLA Accepted for Tividenofusp Alfa, Nipocalimab Outperforms FcRn Blockers
Published: | Updated:
Neurology News Network. for the week ending July 12, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 11, 2025.
Here's some of what is coming soon to NeurologyLive® this week.
Salanersen Shows Promise in Phase 1, MESA Open-Label Data Released, Fenfluramine Meets End Points in Phase 3 GEMZ Trial
Published: | Updated:
Neurology News Network. for the week ending July 5, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 4, 2025.
Here's some of what is coming soon to NeurologyLive® this week.
Eptinezumab Improves Medication Overuse Headache, Submission for GTx-104 in Subarachnoid Hemorrhage, FDA Expands Indication for Vizamyl PET Imaging
Published: | Updated:
Neurology News Network. for the week ending June 28, 2025. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Atogepant Outperforms Topiramate, IND Accepted for ORX142, Prasinezumab Heads to Phase 3 Parkinson Disease Studies
Published: | Updated:
Neurology News Network. for the week ending June 21, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 20, 2025.
Researchers uncover a latent infection model for Creutzfeldt-Jakob disease, revealing insights into its mysterious origins and potential triggers.
Here's some of what is coming soon to NeurologyLive® this week.
Once-Nightly Oxybate Reduces Sleep-Related Eating, Samelisant Improves Excessive Daytime Sleepiness, Tirzepatide's Impact on OSA and Obesity
Published: | Updated:
Neurology News Network. for the week ending June 14, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 13, 2025.
Here's some of what is coming soon to NeurologyLive® this week.
RGX-202 Shows Continued Promise in DMD, AJ201 Meets End Points in Spinal and Bulbar Muscular Atrophy, Ponesimod Effect Sustained Over Long-Term
Published: | Updated:
Neurology News Network. for the week ending June 7, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 6, 2025.
Here's some of what is coming soon to NeurologyLive® this week.
ADDRESS-LC Study of Long COVID Initiated, Phase 4 Trial Testing IVIg Transition to Efgartigimod, Lack of Rebound Effect Seen in Ozanimod
Published: | Updated:
Neurology News Network. for the week ending May 31, 2025. [WATCH TIME: 4 minutes]
Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
2
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
3
How MS Understanding Has Evolved: Activity, Impact, and Progression
4
Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues
5